Ono Pharmaceutical Co Ltd 2024 Sustainability Report
The report describes the company's FY2023 progress toward decarbonization, including a 46.2% Scope 1+2 reduction and a 42.5% group renewable energy usage rate. It also highlights support for the TNFD recommendations and registration as a TNFD Adopter, with expanded biodiversity and nature-risk analysis. Human-capital disclosures cover training, diversity, employee engagement, health management and flexible work initiatives. Selected environmental and social sustainability data received limited independent assurance.
Company: Ono Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Sustainability Report
Pages: 205
Back to company
Ono Pharmaceutical Co Ltd
Sustainability Report
The report describes the company's FY2023 progress toward decarbonization, including a 46.2% Scope 1+2 reduction and a 42.5% group renewable energy usage rate. It also highlights support for the TNFD recommendations and registration as a TNFD Adopter, with expanded biodiversity and nature-risk analysis. Human-capital disclosures cover training, diversity, employee engagement, health management and flexible work initiatives. Selected environmental and social sustainability data received limited independent assurance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Published
Nov 1, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees